Restalyst Pte Ltd of Singapore at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

Restalyst Pte Ltd

50 Loyang Way, 508743 Singapore
Singapore
Telephone +6565433640
Fax +6565433645
restalyst.info@reste-group.om

This company is co-exhibitor of
Singapore Manufacturing Federation

Hall map

MEDICA 2019 hall map (Hall 3): stand G74-01

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

NPC-REAAD™

NPC-REAAD™ is an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma.

 It uses proprietary proteins developed by Restalyst to identify specific IgA antibody to EA seromarker segment.
 
Detection of EA is associated with higher specificity in comparison to other EBV related markers, resulting in fewer false positive during screening. This is particularly important and is a feature that our customers especially value with NPC-REAAD™. Fewer false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments.

More Less

Product category: Diagnostic tests for cancer

GC-REAAD™

GC-REAAD™ is an in-vitro diagnostic intended for early detection of gastric carcinoma using a patented biomarker. This biomarker was discovered to be expressed at high levels in the patient’s plasma samples. Additionally, risk factor for gastric cancer like Helicobacter pylori (H. pylori) infection, does not influence the biomarkers expression levels within plasma.
 
The competition between the patented biomarker and its specific antibodies is the gist of how GC-REAAD™ functions. Positive or negative results obtained through calculations help to determine the patients’ status of gastric cancer.

More Less

Product category: Diagnostic tests for cancer

HCC-REAAD™

HCC-REAADTM is an in-vitro diagnostic intended for early detection of hepatocellular carcinoma using a patented biomarker. Elevated levels of this biomarker were identified within hepatocellular carcinoma patients’ plasma. Internal research studies by Restalyst indicated that this patented biomarker produces better sensitivity than AFP.

More Less

About us

Company details

Established in 2007, Restalyst is a trusted provider of innovative, reliable and clinically-proven diagnostic solutions to the medical and healthcare industry.
 
We are a fully integrated company that generates the full product pipelines from scientific research to in-house developmental work of patented technology.
 
Our key products include immunoassays for early diagnosis and sensitive detection of oncology, infectious, neurodegenerative and other diseases.
 
Our R&D and production facilities are certified for compliance to EN ISO13485:2016.

More Less